Roivant Sciences Ltd.

Healthcare · Biotechnology · United Kingdom

Last price 36.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 26.66B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh...